Boehringer Ingelheim

This early-stage study tests a new medicine called BI 3000202 in 16 adults with rare immune disorders like Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the medicine is safe and how the body proce…

This study follows 2,000 people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who are taking nintedanib. Researchers want to see how the drug affects lung function, quality of life, and survival over time. Participants are already part of the EUSTAR regis…

This study tests a new experimental drug, BI 1701963, that blocks a protein called KRAS which makes some cancers grow faster. The drug is given alone or with an approved cancer medicine, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not respo…

This early-stage trial tests a new drug, BI 764532, in adults with a type of brain tumor (glioma) that has a specific marker called DLL3. The drug is designed to help the body's immune cells recognize and attack the tumor. The main goal is to find the highest safe dose, and parti…

This study tests a new medicine, BI 771716, against an existing treatment (pegcetacoplan) for geographic atrophy, a progressive eye disease that causes vision loss. About 202 adults aged 50 and older will receive eye injections every 4 weeks for over a year. The goal is to see if…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with another drug called ezabenlimab. The goal is to find a safe dose and see if the combination c…

This study tests a new drug, BI 764532, combined with chemotherapy for adults with advanced small cell lung cancer that returned after prior treatment. The goal is to find the safest dose and see if the combo helps control the cancer. About 69 participants will receive the treatm…

This early-stage study tests a new daily pill, zongertinib, in adults with advanced solid tumors (including lung cancer) that have HER2 gene changes and haven't responded to prior treatments. The first part finds the best dose; the second part checks if the drug shrinks tumors. P…

This early-stage study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that didn't respond to previous treatments. Participants receive up to three antibodies: two that help the immune system fight cancer, one that blocks tumor growth s…

This study looks at whether a new medicine called survodutide helps people with obesity burn more energy and fat compared to an existing drug, semaglutide. About 64 adults aged 18 to 65 with a BMI between 30 and 45 will receive weekly injections for several months. Researchers wi…

This study monitors the long-term safety of the drug Ofev in patients with systemic scleroderma-associated interstitial lung disease (SSc-ILD) in Japan. Researchers are tracking side effects, especially stomach issues like diarrhea and nausea, that occur in everyday use. About 58…

This study looks at how different levels of liver problems (mild, moderate, severe) affect the way the body handles a single dose of a medicine called BI 1584862. It includes 43 adults aged 18-80, both with and without liver issues. Participants take the medicine once and are mon…

This study compares how two different versions of the medicine survodutide are absorbed by the body. It involves 100 healthy adults aged 18-65 with a BMI between 27 and 40. Participants receive weekly injections for about 28 weeks, and researchers measure drug levels in the blood…

This study collects blood samples from 102 people with non-small cell lung cancer, colorectal cancer, or pancreatic cancer to track genetic changes in their tumors over time. Participants receive standard treatments, and researchers analyze DNA from the blood to see how it relate…

This study looks at medical records from nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. The goal is to understand how these patients are treated in everyday practice and how long they live. No new treatments are tested; instead, researchers g…